IPP Bureau
Philips Respironics agrees to pay $1.1 billion settlement after CPAP machine recall
By IPP Bureau - May 01, 2024
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data
By IPP Bureau - May 01, 2024
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion
By IPP Bureau - May 01, 2024
2024 full-year revenue guidance raised by US$ 2 billion
Granules India announced ANDA Approval for Colchicine Capsules
By IPP Bureau - May 01, 2024
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Lonza launches AI-enabled Route Scouting Service to accelerate small molecule development
By IPP Bureau - April 30, 2024
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Gland Pharma appoints Satnam Singh Loomba as COO
By IPP Bureau - April 29, 2024
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Gland Pharma receives approval for cetrorelix acetate for injection
By IPP Bureau - April 29, 2024
AstraZeneca’s Truqap plus Faslodex recommended for approval in the EU by CHMP for cancer treatment
By IPP Bureau - April 29, 2024
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Glenmark receives ANDA approval for acetaminophen and ibuprofen tablets
By IPP Bureau - April 29, 2024
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA
Jubilant Pharmova announces completion of USFDA audit of Radiopharmaceuticals manufacturing facility at Montreal
By IPP Bureau - April 28, 2024
The USFDA has issued 5 observations pursuant to the completion of audit
Parexel and Palantir to accelerate clinical data delivery and power clinical outcomes for patients
By IPP Bureau - April 28, 2024
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Bafna Pharmaceuticals inaugurates Quality Control Lab
By IPP Bureau - April 28, 2024
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
Apollo HealthCo to raise Rs. 2,475 crore from Advent International
By IPP Bureau - April 28, 2024
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Zydus receives final approval from USFDA for Tretinoin Cream
By IPP Bureau - April 28, 2024
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
Evonik expands capacity for customized Resomer powder biomaterials
By IPP Bureau - April 28, 2024
New solvent-free micronization technology expanded at the Darmstadt site in Germany
